髂股静脉支架治疗症状性梗阻:东南亚人群5年临床与支架结局
单中心回顾性分析76例(98肢)髂股静脉支架患者,中位随访65.3个月,5年一期、辅助一期和二期通畅率分别为88.2%、92.5%和98.9%,支架相关并发症罕见,多数再干预发生在早期。
要点
- 5年二期通畅率达98.9%,支架治疗安全持久。
- 非血栓性髂静脉病变5年一期通畅率92.0%,优于血栓后综合征和急性深静脉血栓。
- 通畅率丧失多发生在第一年内,与抗凝依从性差相关。
核心结论
- 专用静脉支架治疗症状性髂股静脉梗阻安全持久,东南亚人群长期通畅率和临床结局良好。
研究设计与样本
- 单中心回顾性研究,纳入2015至2020年接受髂股静脉支架的76例患者(98肢),中位随访65.3个月。
主要发现
- 5年累积一期、辅助一期和二期通畅率分别为88.2%、92.5%和98.9%。
- 非血栓性髂静脉病变、血栓后综合征和深静脉血栓的5年一期通畅率分别为92.0%、77.8%和62.5%。
- 支架相关并发症罕见,骨折1.3%,移位1.3%;支架闭塞率(每肢)8.2%。
- 5年无溃疡率82.7%,疼痛缓解率91.8%,持续肿胀缓解率53.1%。
关键数值与推荐
- 82.6%肢体为非血栓性髂静脉病变,9.2%为血栓后综合征,8.2%为急性深静脉血栓。
- 技术成功率100%。
- 通畅率丧失主要发生在第一年内,多因不依从和抗凝不充分。
临床怎么用
- 髂股静脉支架可作为症状性梗阻的长期治疗策略。
- 应重视手术技术、流入道优化和抗血栓治疗依从性,以减少早期再干预。
局限性
- 单中心回顾性设计,样本量有限,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovenous stenting is the standard of care for symptomatic iliofemoral venous obstruction with good short-term patency. We present our long-term outcomes in a Southeast Asian cohort. METHODS: We conducted a single-center retrospective review of 76 patients (98 limbs) who underwent iliofemoral venous stenting between 2015 and 2020. Clinical data and stent outcomes were analyzed over a median follow-up of 65.3 months. Primary, assisted primary, and secondary patency were reviewed using Kaplan-Meier analysis. Stent-related complications, long-term clinical outcomes and factors associated with stent occlusion, were assessed. RESULTS: Of 98 limbs, 82.6% had nonthrombotic iliac vein lesions, 9.2% post-thrombotic syndrome, and 8.2% acute deep vein thrombosis. A 100% technical success rate was achieved. The 5-year cumulative primary, assisted primary, and secondary patency rates were 88.2%, 92.5%, and 98.9%, respectively. Primary patency for stenting for nonthrombotic iliac vein lesion, post-thrombotic syndrome, and deep vein thrombosis was 92.0%, 77.8%, and 62.5%, respectively. Loss of patency occurred mainly within the first year, largely from noncompliance and inadequate anticoagulation. Stent-related complications were rare (fracture 1.3%, migration 1.3%). The rate of stent occlusion (per limb) was 8.2%. At 5 years, ulcer-free rate was 82.7%, pain relief 91.8%, and sustained swelling relief 53.1%. No patient required major amputation, and all-cause mortality was unrelated to venous disease. CONCLUSIONS: Dedicated venous stenting for symptomatic iliofemoral obstruction is safe and durable, with good long-term patency and clinical outcomes in this Southeast Asian cohort. Most reinterventions occurred early, highlighting the importance of procedural technique, inflow optimization, and adherence to antithrombotic therapy. These data support endovenous stenting as a long-term treatment strategy for iliofemoral venous obstruction.
引用
- Lim YS, Prakash PS, Hong Q, et al. Long-term efficacy following venous stenting for symptomatic iliofemoral venous obstruction: 5 year clinical and stent outcomes in a Southeast Asian population. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 41616851. doi:10.1016/j.jvsv.2026.102449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。